JPRN-UMIN000014795已完成3 期
Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC) - Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 170 人开始时间: 2014年8月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies except carcinoma in situ or intramucosal tumor curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Fever of 38 degrees Celsius or higher 4) Pregnant or lactating women, women of childbearing potential, or women within 28 days after delivery 5) Psychiatric disease 6) Patients requiring systemic steroids medication 7) Interstitial pneumonia, pulmonary fibrosis 8) Serious co-existing illness 9) Unstable angina pectoris within 3 weeks, or with a history of myocardial infarction within 6 months 10) Impossible to use both iodine and gadolinium due to being allergic to contrast agent 11) Uncontrolled diabetes mellitus or routine administration of insulin
研究者
相似试验
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-ITEORTC AISBL/IVZW118
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)118
未知
Unknown
Open-label, multicenter study to evaluate the safety and efficacy of oral etoposide and iv cisplatin for patients with advanced or recurrent cervical cancerCervical cancerJPRN-jRCT2080221037ippon Kayaku Co., Ltd.40
进行中（未招募）
不适用
A phase II, multicenter study of etoposide, aracytin, dexamethasone and bortezomib in patients affected by relapsed/refractory multiple myeloma previously treated with thalidomide - NDEUCTR2006-002588-22-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
已完成
3 期
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung CancerSmall Cell Lung CancerNCT00349492Clinical Research Center for Solid Tumor, Korea372